Compare Global X Artificial Intelligence & Technology ETF (AIQ) vs Becton Dickinson and Co (BDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Artificial Intelligence & Technology ETF vs Becton Dickinson and Co — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $63.79, while Becton Dickinson and Co trades at $181.29 (market cap $49.41B). The key difference: Becton Dickinson and Co pays a 2.32% dividend while Global X Artificial Intelligence & Technology ETF pays none, and Becton Dickinson and Co is trading nearer its 52-week high, Global X Artificial Intelligence & Technology ETF nearer its low. Which is the better fit depends on your goals.
| AIQ | BDX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $185.39 |
52-Week Low | $43.88 | $138.62 |
Market Cap | — | $49.41B |
Enterprise Value | — | $65.51B |
Dividend Yield | — | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIQ, the Global X Artificial Intelligence & Technology ETF, trades at $63.79, up 0.44% on the day, with a bullish technical signal driven by moving averages. The ETF has gained attention for outperforming broader indices, with recent news highlighting its 25% gain and positioning in the AI sector. Key resistance lies at $64, while support is near $63.
The outlook remains positive due to strong momentum in AI investments, but risks include sector volatility and high valuations. Analyst sentiment is generally optimistic, with the ETF seen as a diversified play on AI growth, though the absence of dividend income and fee considerations may weigh on long-term returns.
BDX trades at $180.64, up 0.56% today, near its consensus price target of $183. The stock shows bullish technical signals with strong moving averages and recent earnings beats in Q2 2026. Revenue growth is steady, with Q3 2026 reaching $5 billion, though margins face pressure from tariffs. The company maintains a Dividend Aristocrat status with consistent payouts.
Outlook is cautiously optimistic with analyst consensus leaning buy, but risks include margin compression and debt levels. The stock offers stability through dividends and sector resilience, yet investors should monitor earnings sustainability and competitive threats in the medical technology space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Artificial Intelligence & Technology ETF
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →
